These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28296710)

  • 1. Protracted Lhermitte Sign After Cisplatin and Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
    Gutschenritter T; Matthiesen C; Razaq M
    Am J Ther; 2018; 25(4):e490-e492. PubMed ID: 28296710
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients.
    Orlandi E; Iacovelli NA; Rancati T; Cicchetti A; Bossi P; Pignoli E; Bergamini C; Licitra L; Fallai C; Valdagni R; Cavallo A
    Oral Oncol; 2018 Nov; 86():266-272. PubMed ID: 30409311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma.
    Jiang C; Wang H; Xia C; Dong Q; Chen E; Qiu Y; Su Y; Xie H; Zeng L; Kuang J; Ao F; Gong X; Li J; Chen T
    Cancer; 2019 Apr; 125(7):1081-1090. PubMed ID: 30521105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
    Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
    Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olfactory event-related potentials: a new approach for the evaluation of olfaction in nasopharyngeal carcinoma patients treated with chemo-radiotherapy.
    Galletti B; Santoro R; Mannella VK; Caminiti F; Bonanno L; De Salvo S; Cammaroto G; Galletti F
    J Laryngol Otol; 2016 May; 130(5):453-61. PubMed ID: 26931794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
    Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
    Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous steroid regimen for radiation-induced hypoglossal nerve palsy.
    McDowell LJ; Jacobson MC; Levin W
    Head Neck; 2017 Feb; 39(2):E23-E28. PubMed ID: 27704653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Concurrent chemotherapy with different dose regimens of cisplatin for nasopharyngeal carcinoma using intensity-modulated radiation therapy: a phase II prospective randomized controlled trial].
    Liu S; Han F; Chen C; Zeng L; Sun X; Lu T
    Zhonghua Zhong Liu Za Zhi; 2014 Oct; 36(10):778-82. PubMed ID: 25567311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Planned Gamma Knife Boost After Chemoradiotherapy for Selected Sinonasal and Nasopharyngeal Cancers.
    Díaz-Martínez JA; Esquenazi Y; Martir M; Citardi MJ; Karni RJ; Blanco AI
    World Neurosurg; 2018 Nov; 119():e467-e474. PubMed ID: 30071329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
    Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC).
    Jagdis A; Laskin J; Hao D; Hay J; Wu J; Ho C
    Am J Clin Oncol; 2014 Feb; 37(1):63-9. PubMed ID: 23111356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMRT with simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer: plan evaluation and treatment outcome.
    Kim JW; Cho JH; Keum KC; Kim JH; Kim GE; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2012 Dec; 42(12):1152-60. PubMed ID: 23077243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
    Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
    BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.